WHO5, ICC, and IWG classification distributions for the cohort, and clinical findings of IWG classes. After reclassification of our WHO4R-based 2016-to-2022 cohort into WHO5/ICC, most of the cohort (84%/87%) remained as MDS. Panels A and B show the WHO5 and ICC MDS subtype distributions, respectively. Cases reclassified as non-MDS entities in WHO5/ICC were 13%/12% oCMML, 2%/1% AML, and 1%/<1% CCUS, respectively. All cases in the cohort could be assigned into IWG molecular classes (panel C, n for each class given in parentheses). The molecular classes had variable clinical findings (panel D, n for each class given in parentheses). Colors are relative to the medians for all patients, which were: age, 71.6 years; WBC, 2.8 × 109/L; HGB, 9.1 g/dL; PLT, 85 × 109/L; and oCMML, 13%. Classes with <2% of the whole cohort were not subanalyzed due to low sample size: der(1;7) (n = 2), SRSF2 (n = 3), ZRSR2 (n = 3), and AML-like (n = 7, of which 6 of 7 were reclassified to AML instead of MDS by ICC and/or WHO5). ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, compared with remaining patients in the cohort. HGB, hemoglobin; NOS, not otherwise specified; PLT, platelets; WBC, white blood cell count.
